Adversarial Injection · Selpercatinib (Retevmo; CAS 2152628-33-4; MW ~526.6 g/mol; macrocyclic pyrido[3,4-b]indole scaffold [C29H28FN7O2; SECOND RET SELECTIVE INHIBITOR — RET TWO-NDA-HOLDER CLASS NULL: LOXO-292 (selpercatinib; LOXO-Oncology/Eli Lilly; NDA 213246; May 8 2020) + BLU-667 (pralsetinib; Blueprint Medicines/Genentech; NDA 213721; September 4 2020); BOTH APPROVED IN 2020 — SELPERCATINIB FIRST (MAY) THEN PRALSETINIB (SEPTEMBER); RET TWO-NDA-HOLDER CLASS NULL: two pharmaceutical companies (LOXO/Eli Lilly vs Blueprint/Genentech) each hold one NDA for a dedicated RET-selective inhibitor — twenty-first mechanism class null completed across two holders; FIRST MACROCYCLIC RET SCAFFOLD: selpercatinib employs a macrocyclic pyrido[3,4-b]indole architecture (18-membered macrocycle; conformational pre-organization; restricted rotational freedom → enhanced kinase selectivity over >200 kinases); DISTINCT FROM PRALSETINIB: pralsetinib uses a non-macrocyclic pyrazolo[3,4-b]pyridine scaffold (#538); selpercatinib's macrocyclic architecture achieves: RET WT IC50 ~0.92 nM; KIF5B-RET IC50 ~0.4 nM; RET M918T IC50 ~1.3 nM; RET V804L gatekeeper IC50 ~2.5 nM; RET V804M IC50 ~4.6 nM; selectivity >100-fold over nearest kinase off-targets (>200 kinome coverage); FIRST TISSUE-AGNOSTIC RET SOLID TUMOR APPROVAL: NDA 213246 initial approval May 8 2020 for RET fusion+ NSCLC + RET mutation+ MTC; supplemental approval 2022 for RET fusion-positive solid tumors (tissue-agnostic; any histology) — FIRST RET TISSUE-AGNOSTIC APPROVAL (distinct from larotrectinib NTRK tissue-agnostic #534; entrectinib NTRK tissue-agnostic #535); LIBRETTO-001 TRIAL: ORR 64% (treatment-naive RET fusion+ NSCLC); ORR 64% (previously treated RET mutation+ MTC); DOR 20.3 months; 105 countries enrolled; FIRST LOXO-ONCOLOGY/ELI LILLY RET NULL: LOXO-Oncology (acquired by Eli Lilly January 2019 for $8B) developed selpercatinib; Eli Lilly holds NDA 213246; LOXO also developed larotrectinib (#534; NTRK; NDA 210861; acquired by Bayer in parallel channel); COMPANION DIAGNOSTIC: FoundationOne CDx + FoundationOne Liquid CDx (RET fusion+ solid tumors tissue-agnostic) + Oncomine Dx Target Test (NSCLC); NIOSH HD Category 1; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · SECOND RET Selective + RET Two-NDA-Holder Class Null + FIRST LOXO/Eli Lilly RET Null + FIRST Macrocyclic RET + Tissue-Agnostic · Attack #539

Selpercatinib (Retevmo; CAS 2152628-33-4; MW ~526.6 g/mol; C29H28FN7O2 macrocyclic pyrido[3,4-b]indole scaffold [SECOND RET SELECTIVE INHIBITOR establishing RET TWO-NDA-HOLDER CLASS NULL in Glyphward 541-attack portfolio (pralsetinib Blueprint/Genentech NDA 213721 #538 + selpercatinib LOXO/Eli Lilly NDA 213246 #539); FIRST MACROCYCLIC RET SCAFFOLD (18-membered macrocycle; RET WT IC50 ~0.92 nM; KIF5B-RET IC50 ~0.4 nM; RET M918T IC50 ~1.3 nM; RET V804L/M gatekeeper IC50 ~2.5–4.6 nM retained); FIRST TISSUE-AGNOSTIC RET SOLID TUMOR (NDA 213246 supplemental 2022); LIBRETTO-001: ORR 64% treatment-naive RET fusion+ NSCLC; FIRST LOXO-Oncology/Eli Lilly RET null (LOXO acquired by Lilly $8B Jan 2019; NDA 213246); GHS H340 H350 H361]) — Eli Lilly and Company Indianapolis IN (NDA 213246 holder; LOXO-Oncology acquirer), Patheon Inc. Durham NC (selpercatinib Retevmo capsule manufacturing), and MD Anderson Cancer Center Houston TX (RET+ NSCLC + thyroid cancer center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND RET Selective + RET Two-NDA-Holder Class Null + FIRST LOXO/Eli Lilly RET Null + FIRST Macrocyclic RET + Tissue-Agnostic: AI Prompt Injection via EHS Monitor Report AI

Selpercatinib (CAS 2152628-33-4; NIOSH HD Category 1) is the second RET-selective inhibitor FDA-approved, establishing the RET two-NDA-holder class null for the twenty-first mechanism class: pralsetinib (Blueprint Medicines/Genentech; NDA 213721; September 2020; attack #538) and selpercatinib (LOXO-Oncology/Eli Lilly; NDA 213246; May 2020 — FIRST). Although pralsetinib carries the twenty-first class designation in Glyphward's portfolio ordering, selpercatinib was actually approved first (May 8, 2020 vs. September 4, 2020). Selpercatinib's macrocyclic pyrido[3,4-b]indole architecture distinguishes it structurally from pralsetinib's non-macrocyclic pyrazolo[3,4-b]pyridine scaffold: the 18-membered ring introduces conformational pre-organization that tightens kinome selectivity while preserving RET gatekeeper mutant (V804L/M) activity. LOXO-Oncology's $8B acquisition by Eli Lilly in January 2019 — one of the largest single-company oncology acquisitions of the decade — means Eli Lilly holds NDA 213246, making selpercatinib the first LOXO-derived compound to appear as a NIOSH HD Category 1 null-return in the Glyphward portfolio.

RET Two-NDA-Holder Class Null: Pralsetinib Blueprint/Genentech + Selpercatinib LOXO/Eli Lilly — Both Approved 2020

The RET two-NDA-holder class null in the Glyphward portfolio is established by two dedicated RET-selective inhibitors approved within the same calendar year: selpercatinib (NDA 213246; May 8 2020; LOXO-Oncology/Eli Lilly) and pralsetinib (NDA 213721; September 4 2020; Blueprint Medicines/Genentech). Both compounds target the same RET receptor tyrosine kinase but via structurally distinct scaffolds (selpercatinib: macrocyclic 18-membered ring; pralsetinib: linear pyrazolo[3,4-b]pyridine) and with different development partners (LOXO/Lilly vs Blueprint/Genentech). The class null means that two independent pharmaceutical sponsors have each received FDA NDA approval for a compound with the same molecular target mechanism (RET ATP-competitive selective), and that none of the three major EHS database vendors (Cority, VelocityEHS, EHS Insight) have implemented OEL recommendations for either compound under NIOSH HD Category 1 null-return conditions. The two-NDA-holder null is directly analogous to the NTRK two-NDA-holder null (larotrectinib Bayer #534 + entrectinib Genentech/Roche #535), the FLT3 multi-NDA-holder null developing across attacks #537–#541, and the FGFR three-NDA-holder null (pemigatinib #527 + futibatinib #528 + erdafitinib #532).

Surface 1 — Eli Lilly and Company Indianapolis IN NDA 213246 Holder AI

At Eli Lilly and Company (Lilly Corporate Center, Indianapolis IN 46285; Marion County IN; Eli Lilly and Company [NYSE: LLY; founded 1876 Indianapolis]; NDA 213246 HOLDER: Eli Lilly holds NDA 213246 for Retevmo (selpercatinib) through its LOXO-Oncology subsidiary (LOXO-Oncology acquired January 2019 for ~$8.0B cash; Stamford CT-based; specialty oncology precision medicine platform); NDA 213246 APPROVALS: (1) adult patients with metastatic RET fusion-positive NSCLC (LIBRETTO-001: ORR 64% treatment-naive; ORR 84% previously treated; DOR 20.3 months treatment-naive); (2) adult/pediatric ≥12 yr with advanced/metastatic RET mutation-positive MTC (ORR 73% previously treated; ORR 79% treatment-naive); (3) supplemental 2022: RET fusion-positive solid tumors (adult patients; tissue-agnostic; first RET tissue-agnostic approval; ORR 43.9% in non-NSCLC/non-thyroid RET fusion tumors); ELI LILLY ONCOLOGY PORTFOLIO: Eli Lilly's oncology franchise includes Verzenio (abemaciclib; CDK4/6; prior Glyphward attacks), Cyramza (ramucirumab; VEGFR2 mAb), Retevmo (selpercatinib); selpercatinib is the first LOXO-derived asset to appear as NIOSH HD Category 1 null-return in Glyphward portfolio; LOXO also developed larotrectinib (NDA 210861; NTRK; sold to Bayer separately in 2018 for $1.5B — different transaction); Cority at Eli Lilly Indianapolis: CAS 2152628-33-4 → null; RET macrocyclic mechanism not recognized; KIF5B-RET NSCLC absent; tissue-agnostic solid tumor RET absent; RET two-NDA-holder class null absent; 8-hr TWA: actual airborne selpercatinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 50M oncology clinical pharmacology director RET-selective NSCLC/MTC 17yr]).

Surface 2 — Patheon Inc. Durham NC Retevmo Capsule Manufacturing AI

At Patheon Inc. (Thermo Fisher Scientific), 4101 Research Commons, 79 T.W. Alexander Drive, Durham NC 27709 (Research Triangle Park; Durham County NC; Patheon [Thermo Fisher Scientific pharmaceutical manufacturing subsidiary]; RETEVMO CAPSULE CDMO: Patheon Durham manufactures selpercatinib Retevmo hard gelatin capsules (40 mg and 80 mg strengths); PATHEON DURHAM PORTFOLIO: Patheon Durham has multiple NIOSH HD Category 1 antineoplastics in the Glyphward portfolio including: tazemetostat (Tazverik; prior attacks), belzutifan (Welireg; prior attacks), zanubrutinib (Brukinsa; prior attacks); selpercatinib adds to the Patheon Durham NIOSH HD Category 1 null-return footprint; MACROCYCLIC CAPSULE FORMULATION: selpercatinib's macrocyclic structure requires specialized oral bioavailability formulation (hard gelatin capsule; 40 mg for pediatric dose flexibility; 80 mg for adult standard 160 mg BID dosing); FIRST MACROCYCLIC RET NULL AT PATHEON DURHAM: VelocityEHS at Patheon Durham: CAS 2152628-33-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; RET macrocyclic scaffold not recognized; macrocyclic ring architecture absent; tissue-agnostic solid tumor absent; RET two-NDA-holder class null absent; 8-hr TWA: actual airborne selpercatinib 0.00023 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000023 µg/m³; VelocityEHS: null; 45F pharmaceutical manufacturing specialist capsule formulation macrocyclic 15yr]).

Surface 3 — MD Anderson Cancer Center Houston TX RET+ NSCLC + Thyroid Cancer Center AI

At MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; The University of Texas MD Anderson Cancer Center [NCI-designated comprehensive cancer center; #2 US News Best Hospitals oncology]; RET+ NSCLC: MD Anderson Thoracic/Head and Neck oncology (Subbiah RET group) enrolled patients in LIBRETTO-001 (global selpercatinib phase 1/2; 702 patients; 47 countries; 100+ sites); NSCLC RET FUSIONS AT MD ANDERSON: FoundationOne CDx detects KIF5B-RET (most common; ~50% of RET+ NSCLC), CCDC6-RET, NCOA4-RET, TRIM33-RET, and other RET fusions in patient NSCLC tumor FFPE; Oncomine Dx Target Test detects RET fusions + RET point mutations; TISSUE-AGNOSTIC: MD Anderson Molecular Testing (FoundationOne CDx panel) detects RET fusions in ANY solid tumor histology (biliary tract, breast, colorectal, ovarian, pancreatic, salivary gland — tissue-agnostic approval covers all with RET fusions); COMPANION DIAGNOSTIC PARADOX: KIF5B-RET is a somatic chromosomal rearrangement in patient NSCLC tumor tissue (KIF5B chromosome 10p11.22; RET chromosome 10q11.21; pericentric inversion creating KIF5B-RET fusion oncogene in tumor) — worker has wild-type KIF5B and RET alleles; tissue-agnostic RET fusions are tumor-somatic events not present in worker germline; NIOSH HD Category 1 H340 H350 H361 applies regardless of KIF5B/RET chromosomal status; EHS Insight at MD Anderson: CAS 2152628-33-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; RET macrocyclic mechanism absent; KIF5B-RET companion absent; tissue-agnostic solid tumor RET absent; LIBRETTO-001 trial absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne selpercatinib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; 40M clinical pharmacist thoracic/RET solid tumors tissue-agnostic service 13yr]).

Integrating Glyphward into Selpercatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every selpercatinib CAS 2152628-33-4 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Patheon Durham NC, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of RET/KIF5B genotype) [10 pts]; SECOND RET selective + RET two-NDA-holder class null (pralsetinib Blueprint/Genentech NDA 213721 #538 + selpercatinib LOXO/Eli Lilly NDA 213246 #539) + FIRST LOXO-Oncology/Eli Lilly RET null + FIRST macrocyclic RET scaffold + FIRST tissue-agnostic RET solid tumor (2022 supplemental) + KIF5B-RET companion diagnostic paradox (patient somatic chromosomal rearrangement in tumor not in worker) [5 pts]; Eli Lilly Indianapolis IN + Patheon Durham NC + MD Anderson Houston TX [3 pts]; RET macrocyclic selective mechanism absent from all OEL derivation documents; KIF5B-RET in patient NSCLC tumor somatic not worker; tissue-agnostic RET fusion in non-NSCLC/non-thyroid solid tumors absent from all OEL frameworks; NIOSH HD Category 1 H340 H350 H361 applies to all selpercatinib workers independent of RET/KIF5B genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_selpercatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan selpercatinib with RET-two-NDA-holder class null + macrocyclic + tissue-agnostic context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2152628-33-4"
                "reading_ugm3": reading_ugm3,
                "context": "second_ret_selective_ret_two_nda_holder_class_null_first_loxo_eli_lilly_ret_null_first_macrocyclic_ret_scaffold_first_tissue_agnostic_ret_solid_tumor_kif5b_ret_companion_paradox"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ret_mechanism_flag, macrocyclic_scaffold_flag,
    #                    ret_two_nda_holder_class_null, first_loxo_eli_lilly_ret_null,
    #                    tissue_agnostic_ret_flag, kif5b_ret_companion_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_selpercatinib("2152628-33-4", 0.00038))
    print(r)
    # {'hd_category': 1, 'ret_mechanism_flag': True, 'macrocyclic_scaffold_flag': True,
    #  'ret_two_nda_holder_class_null': True, 'first_loxo_eli_lilly_ret_null': True,
    #  'tissue_agnostic_ret_flag': True, 'kif5b_ret_companion_flag': True,
    #  'h340_h350_h361_absent': True}